Avadel Pharmaceuticals plc
AVDL
$0.28
Change (1 day)
$19.09
Year High
$9.50
Year Low
Categories
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Earnings for Avadel Pharmaceuticals plc (AVDL)
Earnings in 2023 (TTM): $-160,777,000
According to Avadel Pharmaceuticals plc's latest financial reports the company's current earnings (TTM) are $-160,777,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Avadel Pharmaceuticals plc
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-160,777,000 | $-160,276,000 |
| 2022 | $-111,439,000 | $-137,464,000 |
| 2021 | $-93,145,000 | $-77,329,000 |
| 2020 | $-5,082,000 | $7.03 M |
| 2019 | $-38,582,000 | $-33,226,000 |
| 2018 | $-113,197,000 | $-95,304,000 |
| 2017 | $91.47 M | $67.25 M |
| 2016 | $-9,718,000 | $-41,276,000 |
| 2015 | $78.39 M | $40.66 M |
| 2014 | $-90,331,000 | $-84,906,000 |
| 2013 | $-54,095,000 | $-42,925,000 |
| 2012 | $-7,930,000 | $-3,228,000 |
| 2011 | $-8,582,000 | $-8,774,000 |
| 2010 | $-8,766,000 | $-8,975,000 |
| 2009 | $-11,439,000 | $-11,439,000 |
| 2008 | $-18,562,000 | $-12,084,000 |
| 2007 | $-39,431,000 | $-37,737,000 |
| 2006 | $-37,319,000 | $-35,201,000 |
| 2005 | $-31,663,000 | $-27,377,000 |
| 2004 | $9.3 M | $12.5 M |
| 2003 | $-3,997,000 | $-3,494,000 |
| 2002 | $2.45 M | $3.01 M |
| 2001 | $-2,860,000 | $-2,874,000 |
| 2000 | $-4,834,000 | $-9,461,000 |
| 1999 | $-6,678,000 | $-6,694,000 |
| 1998 | $-9,059,000 | $-7,812,000 |
| 1997 | $-8,200,000 | $-6,800,000 |
| 1996 | $-8,400,000 | $-6,900,000 |